Jpmorgan Chase & CO Axsome Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

$1.22 Trillion
Q3 2024

A detailed history of Jpmorgan Chase & CO transactions in Axsome Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 212,110 shares of AXSM stock, worth $23.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

212,110

Previous 184,576 14.92%

Holding current value

$23.2 Million

Previous $14.9 Million 28.27%

% of portfolio

0.0%

Previous 0.0%

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Dec 26, 2024	BUY	$78.93 - $95.84 $2.17 Million - $2.64 Million	27,534 Added 14.92%	212,110 $19.1 Million
Q3 2024 Nov 08, 2024	BUY	$78.93 - $95.84 $2.17 Million - $2.64 Million	27,534 Added 14.92%	212,110 $19.1 Million
Q2 2024 Dec 26, 2024	SELL	$65.72 - $80.5 $1.81 Million - $2.22 Million	-27,534 Reduced 12.98%	184,576 $14.9 Million
Q2 2024 Aug 12, 2024	SELL	$65.72 - $80.5 $702,218 - $860,142	-10,685 Reduced 5.47%	184,576 $14.9 Million
Q1 2024 Dec 26, 2024	SELL	$69.39 - $97.64 $1.17 Million - $1.65 Million	-16,849 Reduced 7.94%	195,261 $15.6 Million
Q1 2024 May 10, 2024	BUY	$69.39 - $97.64 $371,652 - $522,959	5,356 Added 2.82%	195,261 $15.6 Million
Q4 2023 Dec 26, 2024	SELL	$57.42 - $83.61 $1.28 Million - $1.86 Million	-22,205 Reduced 10.47%	189,905 $15.1 Million
Q4 2023 Feb 12, 2024	BUY	$57.42 - $83.61 $1 Million - $1.46 Million	17,449 Added 10.12%	189,905 $15.1 Million
Q3 2023 Nov 14, 2023	SELL	$69.25 - $82.21 $53,738 - $63,794	-776 Reduced 0.45%	172,456 $12.1 Million
Q2 2023 Aug 11, 2023	SELL	$58.41 - $90.35 $53,970 - $83,483	-924 Reduced 0.53%	173,232 $12.4 Million
Q1 2023 May 18, 2023	BUY	$58.39 - $75.0 $2.41 Million - $3.1 Million	41,352 Added 31.14%	174,156 $10.7 Million
Q1 2023 May 11, 2023	SELL	$58.39 - $75.0 $2.03 Million - $2.61 Million	-34,773 Reduced 20.75%	132,804 $8.19 Million
Q4 2022 Feb 13, 2023	SELL	$39.94 - $79.72 $171,781 - $342,875	-4,301 Reduced 2.5%	167,577 $12.9 Million
Q3 2022 Nov 14, 2022	SELL	$36.06 - $69.85 $137,857 - $267,036	-3,823 Reduced 2.18%	171,878 $7.67 Million
Q2 2022 Aug 11, 2022	SELL	$21.74 - $46.75 $8,369 - $17,998	-385 Reduced 0.22%	175,701 $6.73 Million
Q1 2022 May 11, 2022	BUY	$23.7 - $41.39 $19,979 - $34,891	843 Added 0.48%	176,086 $7.29 Million
Q4 2021 Feb 10, 2022	BUY	$30.7 - $43.36 $4.57 Million - $6.45 Million	148,780 Added 562.22%	175,243 $6.62 Million
Q3 2021 Nov 12, 2021	BUY	$19.91 - $68.26 $526,878 - $1.81 Million	26,463 New	26,463 $871,000

Others Institutions Holding AXSM

# of Institutions

332

Shares Held

38.3M

Call Options Held

912K

Put Options Held

855K

View Full List

About Axsome Therapeutics, Inc.

Ticker AXSM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,878,000
Market Cap $4.7B
Description
Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's product pipeline includes AXS-05, a therapeutic for the treatment of major depressive disorder and resistant depression disorders; and that is in the Phase III clinic...

More about AXSM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Axsome Therapeutics, Inc. Transaction History